NASDAQ: GH · Industrial Applications and Services · 7 alerts · CIK 1576280
Share price
$144.03Close, Nov 16
Market cap
$19.5B
Shares outstanding
135.29MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Guardant Health, Inc. filings on SEC EDGAR ↗
Guardant Health $550M Debt Financing with U.S. Bank Trust Company, National Association
Guardant Health completed a private offering of $550 million in 0% Convertible Senior Notes due 2032, which included the full exercise of the initial purchasers' option for an additional $50 million. The notes feature an initial conversion price of approximately $208.95 per share, representing a 35% premium over the November 11, 2026 closing price. Proceeds will be used to repurchase a portion of the company's existing 2027 convertible notes, fund capped call transactions, and for general corporate purposes.
Guardant Health reported revenue of $361.0 million for the third quarter of 2026, a 36% increase compared to the same period in 2025. Despite the revenue growth, the company experienced a net loss of $124.4 million for the quarter, driven by increased sales, marketing, and general administrative expenses.
Guardant Health reported Q3 2026 revenue of $361.0 million, a 36% increase year-over-year, driven by strong performance in its Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion and highlighted the FDA approval of Guardant360 CDx as a companion diagnostic for breast cancer.
Term
Q3 2026
“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”
Helmy Eltoukhy, co-founder and co-CEO
“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”
Guardant Health appointed Kevin R. Sayer, former CEO of Dexcom, to its Board of Directors and named Robert A. Parks as Chief Accounting Officer. Mr. Sayer will receive an annual cash retainer of $60,000 and an initial restricted stock unit award valued at $500,000 vesting over three years.
Guardant Health granted performance-based restricted stock units (PSUs) to Co-CEOs Helmy Eltoukhy and AmirAli Talasaz under the 2018 Incentive Award Plan. Each executive received 465,413 PSUs at target, with vesting 100% tied to the company's total shareholder return (TSR) relative to the S&P 500 Index over three-year and five-year periods. The awards include a cap at 100% of target if absolute TSR is negative and require additional post-vesting holding periods.
Guardant Health Insider Musa Tariq Sells $19.2K of Stock
Musa Tariq sold 116 shares of Guardant Health, Inc. at $165.88 a share, worth $19.2K in total on Oct 16, 2026. Shares held after the trade: 11,583 (-1.0%).